Barrister AI
All legislation
ACTRegulation
In force
This is the latest official compilation.Check the official source →
reg 13

Information to be given to individual before first prescription—Act, s 58 (1) (d)

In force
Part 3Accessing voluntary assisted dying and death

13 Information to be given to individual before first prescription—Act, s 58 (1) (d)

(1)

The following information is prescribed:

(a)

the medicine that constitutes the approved substance;

(b)

a statement that the individual is under no obligation to proceed with the administration of the approved substance;

(c)

the business address and telephone number of an approved disposer who is authorised to dispose of the approved substance;

(d)

if the individual has a practitioner administration decision in effect—

(i)

the method by which the approved substance will be administered to the individual; and

(ii)

the expected effects on the individual of the approved substance being administered to the individual; and

(iii)

the period in which the individual is likely to die after the approved substance is administered to the individual; and

(iv)

the potential complications of the approved substance being administered to the individual;

(e)

if the individual has a self-administration decision in effect—

(i)

the business address and telephone number of an approved supplier who can supply the approved substance to the individual; and

(ii)

a statement about the storage requirements and liability under the Act, section 74 (Storage of approved substances); and

(iii)

details about how the individual can prepare and self‑administer the approved substance; and

(iv)

the period during which a prescription for the approved substance is valid; and

(v)

a statement about the effect of the Act, section 68 (Giving approved substances to approved disposer if administration decision revoked—individual or contact person); and

(vi)

a statement about the effect of the Act, section 69 (Giving approved substances to approved disposer if individual dies or contact person appointment ends—contact person); and

(vii)

the expected effects on the individual of self‑administering the approved substance; and

(viii)

the period in which the individual is likely to die after self‑administering the approved substance; and

(ix)

the potential complications of the individual self‑administering the approved substance.

(2)

The information mentioned in subsection (1) must be given to the individual orally and in writing.

Research tools for this sectionPro

The statute text is free to read above. View Pro plans to unlock the case-law research tools for each provision.